{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T18:14:22Z","timestamp":1758046462809,"version":"3.44.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"published-print":{"date-parts":[[2013,1]]},"DOI":"10.1016\/j.pharma.2012.10.002","type":"journal-article","created":{"date-parts":[[2012,11,12]],"date-time":"2012-11-12T19:55:19Z","timestamp":1352750119000},"page":"7-12","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Calcul de la premi\u00e8re dose d\u2019amikacine\u00a0: \u00e9valuation des recommandations posologiques actuelles"],"prefix":"10.1016","volume":"71","author":[{"given":"E.","family":"Jean-Bart","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Debeurme","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Ducher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Bourguignon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.pharma.2012.10.002_bib0005","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1093\/jac\/dkn469","article-title":"Aminoglycoside drugs in clinical practice: an evidence-based approach","volume":"63","author":"Leibovici","year":"2009","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"10.1016\/j.pharma.2012.10.002_bib0010","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/S0002-9610(00)00539-0","article-title":"Should aminoglycoside antibiotics be abandoned?","volume":"180","author":"English","year":"2000","journal-title":"Am J Surg"},{"issue":"5","key":"10.1016\/j.pharma.2012.10.002_bib0015","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1093\/qjmed\/95.5.291","article-title":"Risk factors for nephrotoxicity in elderly patients receiving once-daily aminoglycosides","volume":"95","author":"Raveh","year":"2002","journal-title":"QJM"},{"issue":"3","key":"10.1016\/j.pharma.2012.10.002_bib0020","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1128\/AAC.47.3.1010-1016.2003","article-title":"Aminoglycoside nephrotoxicity: modeling, simulation, and control","volume":"47","author":"Rougier","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"10.1016\/j.pharma.2012.10.002_bib0025","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1093\/jac\/39.6.677","article-title":"Once-daily dosing of aminoglycosides: review and recommendations for clinical practice","volume":"39","author":"Freeman","year":"1997","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"10.1016\/j.pharma.2012.10.002_bib0030","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1128\/AAC.42.4.849","article-title":"Population pharmacokinetic study of amikacin administered once or twice daily to febrile, severely neutropenic adults","volume":"42","author":"Tod","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"issue":"17","key":"10.1016\/j.pharma.2012.10.002_bib0035","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.2165\/11597020-000000000-00000","article-title":"Pharmacological considerations for the proper clinical use of aminoglycosides","volume":"71","author":"Pagkalis","year":"2011","journal-title":"Drugs"},{"key":"10.1016\/j.pharma.2012.10.002_bib0040","unstructured":"ANSM. (Mise au point sur le bon usage des aminosides injectables Internet). ANSM; 2011\u00a0mars. Available de: http:\/\/ansm.sante.fr\/var\/ansm_site\/storage\/original\/application\/3e0d2264e2921c8465d9ad6464e12660.pdf."},{"issue":"6","key":"10.1016\/j.pharma.2012.10.002_bib0045","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1097\/FTD.0b013e3181f675c2","article-title":"Population pharmacokinetic modeling and optimal sampling strategy for Bayesian estimation of amikacin exposure in critically ill septic patients","volume":"32","author":"Delattre","year":"2010","journal-title":"Ther Drug Monit"},{"issue":"2","key":"10.1016\/j.pharma.2012.10.002_bib0050","doi-asserted-by":"crossref","first-page":"R53","DOI":"10.1186\/cc8945","article-title":"Revisiting the loading dose of amikacin for patients with severe sepsis and septic shock","volume":"14","author":"Taccone","year":"2010","journal-title":"Crit Care"},{"issue":"6","key":"10.1016\/j.pharma.2012.10.002_bib0055","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.ijantimicag.2011.01.026","article-title":"Pharmacokinetics of a loading dose of amikacin in septic patients undergoing continuous renal replacement therapy","volume":"37","author":"Taccone","year":"2011","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"10.1016\/j.pharma.2012.10.002_bib0060","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1378\/chest.118.1.146","article-title":"The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting","volume":"118","author":"Ibrahim","year":"2000","journal-title":"Chest"},{"issue":"5","key":"10.1016\/j.pharma.2012.10.002_bib0065","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1046\/j.1365-2796.1998.00379.x","article-title":"The benefit of appropriate empirical antibiotic treatment in patients with bloodstream infection","volume":"244","author":"Leibovici","year":"1998","journal-title":"J Intern Med"},{"issue":"8","key":"10.1016\/j.pharma.2012.10.002_bib0070","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1097\/CCM.0b013e31821b85f4","article-title":"Impact of previous antibiotic therapy on outcome of Gram-negative severe sepsis","volume":"39","author":"Johnson","year":"2011","journal-title":"Crit Care Med"},{"issue":"4","key":"10.1016\/j.pharma.2012.10.002_bib0075","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1128\/AAC.49.4.1306-1311.2005","article-title":"Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatment","volume":"49","author":"Micek","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.pharma.2012.10.002_bib0080","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/CCM.0b013e3181fa41a7","article-title":"Inappropriate antibiotic therapy in Gram-negative sepsis increases hospital length of stay","volume":"39","author":"Shorr","year":"2011","journal-title":"Crit Care Med"},{"issue":"12","key":"10.1016\/j.pharma.2012.10.002_bib0085","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1001\/archsurg.137.12.1353","article-title":"Epidemiology and prognostic determinants of bloodstream infections in surgical intensive care","volume":"137","author":"Harbarth","year":"2002","journal-title":"Arch Surg"},{"issue":"7726","key":"10.1016\/j.pharma.2012.10.002_bib0090","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/S0140-6736(71)92283-5","article-title":"Estimation of creatinine clearance from changing serum-creatinine levels","volume":"2","author":"Jelliffe","year":"1971","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.pharma.2012.10.002_bib0095","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1159\/000065221","article-title":"Estimation of creatinine clearance in patients with unstable renal function, without a urine specimen","volume":"22","author":"Jelliffe","year":"2002","journal-title":"Am J Nephrol"},{"issue":"2","key":"10.1016\/j.pharma.2012.10.002_bib0100","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.medmal.2009.08.011","article-title":"Monitoring aminoglycosides in an intensive care unit","volume":"40","author":"Commandeur","year":"2010","journal-title":"Med Mal Infect"},{"issue":"2","key":"10.1016\/j.pharma.2012.10.002_bib0105","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ijantimicag.2011.03.022","article-title":"Higher than recommended amikacin loading doses achieve pharmacokinetic targets without associated toxicity","volume":"38","author":"G\u00e1lvez","year":"2011","journal-title":"Int J Antimicrob Agents"},{"issue":"5","key":"10.1016\/j.pharma.2012.10.002_bib0110","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1128\/AAC.35.5.944","article-title":"Amikacin pharmacokinetics in patients receiving high-dose cancer chemotherapy","volume":"35","author":"Davis","year":"1991","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1016\/j.pharma.2012.10.002_bib0115","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1177\/0310057X9302100206","article-title":"Aminoglycoside volume of distribution and illness severity in critically ill septic patients","volume":"21","author":"Marik","year":"1993","journal-title":"Anaesth Intensive Care"},{"issue":"7","key":"10.1016\/j.pharma.2012.10.002_bib0120","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1128\/AAC.42.7.1842","article-title":"Dosing of aminoglycosides to rapidly attain pharmacodynamic goals and hasten therapeutic response by using individualized pharmacokinetic monitoring of patients with pneumonia caused by Gram-negative organisms","volume":"42","author":"Kashuba","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.pharma.2012.10.002_bib0125","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1128\/AAC.43.3.623","article-title":"Optimizing aminoglycoside therapy for nosocomial pneumonia caused by Gram-negative bacteria","volume":"43","author":"Kashuba","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"10.1016\/j.pharma.2012.10.002_bib0130","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1097\/FTD.0b013e31818b6b2f","article-title":"Suboptimal aminoglycoside dosing in critically ill patients","volume":"30","author":"Rea","year":"2008","journal-title":"Ther Drug Monit"},{"issue":"1","key":"10.1016\/j.pharma.2012.10.002_bib0135","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2515\/therapie\/2009009","article-title":"Amikacin pharmacokinetics in adults: a variability that question the dose calculation based on weight","volume":"64","author":"Bourguignon","year":"2009","journal-title":"Therapie"},{"issue":"2","key":"10.1016\/j.pharma.2012.10.002_bib0140","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1002\/j.1875-9114.1996.tb02947.x","article-title":"Exploration of once-daily dosing of aminoglycosides through Bayesian simulation","volume":"16","author":"Garrelts","year":"1996","journal-title":"Pharmacotherapy"},{"issue":"11","key":"10.1016\/j.pharma.2012.10.002_bib0150","doi-asserted-by":"crossref","first-page":"803","DOI":"10.2165\/00003088-200140110-00002","article-title":"Individualising aminoglycoside dosage regimens after therapeutic drug monitoring: simple or complex pharmacokinetic methods?","volume":"40","author":"Tod","year":"2001","journal-title":"Clin Pharmacokinet"}],"container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003450912001472?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003450912001472?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T23:29:39Z","timestamp":1757719779000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003450912001472"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["S0003450912001472"],"URL":"https:\/\/doi.org\/10.1016\/j.pharma.2012.10.002","relation":{},"ISSN":["0003-4509"],"issn-type":[{"type":"print","value":"0003-4509"}],"subject":[],"published":{"date-parts":[[2013,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Calcul de la premi\u00e8re dose d\u2019amikacine\u00a0: \u00e9valuation des recommandations posologiques actuelles","name":"articletitle","label":"Article Title"},{"value":"Annales Pharmaceutiques Fran\u00e7aises","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharma.2012.10.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}